Taysha Gene Therapies, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TSHA | SRPT | NGNE | RGNX | NTLA | IONS | |
|---|---|---|---|---|---|---|
| Market cap | 1.42B | 2.01B | 551.91M | 508.96M | 1.72B | 6.67B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -9.4 | 7.8 | -4.8 | -2.6 | -4.8 | -35.0 |
| Price/book | 3.7 | 1.3 | 2.0 | 5.8 | 2.4 | 15.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +11.22% | +7.65% | +3.45% | −30.98% | −12.60% | −45.82% |
| Today | +6.60% | +2.43% | +3.41% | +1.05% | +3.79% | −0.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TSHA news ›Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102…
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
Adapted from iStock, zizar2002 Patients with Rett syndrome have historically had few treatment options—but 2027 could change that. Two gene therapies are at the FDA’s doorstep with strong data showing they can alter the trajectory of the…
Financial Review: Artiva Biotherapeutics (NASDAQ:ARTV) and Taysha Gene Therapies (NASDAQ:TSHA)
Posted by Michael Walen on Oct 11th, 2026 Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will…
Taysha Gene Therapies (NASDAQ:TSHA) versus MediWound (NASDAQ:MDWD) Head to Head Analysis
Posted by Defense World Staff on Oct 9th, 2026 Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare…
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock Has Average Target Price of $12.77 According to Brokerages
Posted by Defense World Staff on Oct 7th, 2026 View Our Latest Stock Report on Taysha Gene Therapies Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net2
- ir.tayshagtx.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.